Text/Yangcheng Evening News all-media reporter Zhang Hua
Photo/Visual China
Recently, the results of the sixth batch of centralized procurement of drugs organized by the state (insulin special) were announced, and the average reduction of 48% is undoubtedly good news for more than 10 million patients who use insulin. Endocrinologists said that after the insulin price reduction, there are drugs that are more convenient to use, have less risk of hypoglycemia, and have fewer side effects, which not only reduces the burden of medication for patients, but also has better compliance, and will also help them receive clinical treatment more regularly.
Controlling blood sugar requires more convenient treatment options
According to the reporter's understanding, many patients have just been diagnosed with diabetes, do not pay attention to active treatment, blood sugar control is not ideal, and finally led to complications. Liu Ping (pseudonym), a patient who has suffered from diabetes for many years, is one of the "disobedient" people. It is reported that he was diagnosed with type 2 diabetes in 2005, and because he was diagnosed with complications of fundus disease, doctors developed an insulin treatment plan for him.
After a period of treatment, Liu Ping's blood sugar has indeed been relatively stable control. But after stabilizing, his mentality changed, and from time to time he relaxed his blood sugar control, such as the human insulin he used, which needed to be injected accurately 30 minutes before the meal. But he always forgot, several times because he forgot the injection time and was admitted to the hospital with low blood sugar.
How to better control blood sugar? Based on Liu Ping's personal situation, the doctor recommended that he change human insulin to insulin analogues. "Clinical studies have shown that the third generation of insulin is more effective in terms of efficacy, and more importantly, it is more convenient to use, the risk of hypoglycemia is smaller, and the side effects are fewer, so for patients without adverse reactions such as allergies, the hidden dangers in terms of efficacy and safety are very low." Professor Mu Yiming of the Department of Endocrinology of the General Hospital of the Chinese People's Liberation Army said in an interview with the media.
"Insulin analogues are more convenient to use. But I can't afford the medicine. Liu Ping said, "My retirement salary is not high, and I don't want to add too much burden to my son." Therefore, without the consent of the doctor, Liu Ping quietly switched to oral hypoglycemic drugs, and as a result, the blood sugar control was not up to standard, and complications were accompanied again, and he had to be hospitalized.
The policy of benefiting the people has played a major role in promoting the treatment of diabetes
Recently, the results of the sixth batch of centralized procurement of drugs (insulin special) organized by the state were announced, and this collection included mealtime human insulin, basic human insulin, premixed human insulin, meal insulin analogue, basic insulin analogue, and premixed insulin analogue, a total of 6 procurement groups, and the procurement cycle was two years. Among them, the largest decline was in the sperm protein zinc recombinant lispro insulin mixed injection in the premixed insulin analog group 25 and 50, and the minimum price of a single dose was only 18.89 yuan, a decrease of 73%.
"This is good, the price is cheap, it can be used, and I am so grateful for the good policies of the country." Liu Ping said.
In this regard, doctors around the world have also said that after the insulin price reduction, the patient's medication burden will be reduced, the patient's compliance will be better, and it will also help them to receive clinical treatment more regularly. The data shows that more than 10 million patients use insulin nationwide. In recent years, China's insulin market has also grown faster than the global average.
"For us Chinese diabetics, if we use second-generation insulin (human insulin) in the past, the actual annual expenditure is about 1500 yuan, and if we use third-generation insulin (insulin analogue), the annual expenditure is 2000-3000 yuan. If the overall decline can be more than 48%, the annual expenditure will fall by about half, coupled with medicare reimbursement, greatly reducing the cost of patients and the burden of medical treatment. Professor Peng Yongde, director of the Department of Secretion and Metabolism of the First People's Hospital Affiliated to Shanghai Jiao Tong University, pointed out in an interview with the media: "This collection is actually more of a policy of benefiting the people, which can play a major role in promoting and helping the treatment of diabetic patients in the mainland." ”
According to the reporter's understanding, according to the work arrangements of the previous national organization of the joint procurement office of drugs, from May 2022, the results of the sixth batch of national drug collection and procurement will be officially implemented, and the specific implementation date will be subject to the notice issued by various localities. Recently, all provinces are actively preparing for the landing, as of now, Fujian, Guangdong, Shanghai, Gansu, Heilongjiang, Yunnan, Liaoning and other places have issued declaration notices. According to the law of collection and mining, after completing the preparation work such as hanging the net, the results of the selection will be officially implemented soon after. When the official landing date, the selected products will generally enter the purchasable state directly from 00:00 on the same day. (For more news, please pay attention to Yangcheng Pie pai.ycwb.com)
Source | Yangcheng Evening News Yangcheng Pie
Editor-in-charge | Wang Moyi